Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics

• Grant number: 13/08711-3
• Support Opportunities: Research Grants - Young Investigators Grants
• Start date: February 01, 2014
• End date: July 31, 2018
• Field of knowledge: Biological Sciences - Biochemistry - Chemistry of Macromolecules
• Principal Investigator: Daniel Martins-de-Souza
• Grantee: Daniel Martins-de-Souza
• Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated research grant(s): 14/10068-4 - Multi-User Equipment approved in grant 13/08711-3: mass spectrometer waters SYNAPT G2-Si HDMS + nanoACQUITY UPLC, AP.EMU
• Associated scholarship(s): 18/10362-0 - Evaluation of the effect of antipsychotics and the cannabidiol in an oligodendrocytes culture treated with cuprizone: implications for myelination, BP.MS; 18/03422-7 - Identification of blood-based biomarkers for late-life depression through proteomics, BP.MS; 17/25055-3 - The role of hnRNPs in oligodendrocytes and their implications on schizophrenia, BP.DR; + associated scholarships 17/18242-1 - Biochemical pathways affected by cannabinoid drugs of human oligodendrocytes, BP.PD; 16/18715-4 - Establishment of the hnRNPs role on schizophrenia through protein interaction network mapping, BP.PD; 17/00025-4 - Establishment of selected reaction monitoring (SRM) technique for proteins of interest in schizophrenia, BP.IC; 16/07948-8 - Relationship between a myelin-associated phosphodiesterase CNP and schizophrenia, BP.MS; 16/04912-2 - Characterization of the mitochondrial proteome and oxidative biochemical profile of neural cells derived from iPSCs from patients with schizophrenia, BP.MS; 16/07332-7 - The role of 14-3-3 and Ephrin signaling pathways on cellular communication between neurons-astrocytes and the functioning of the synapse tripartite, BP.DR; 15/23049-0 - Employing human oligodendroglial cell cultures and glutamatergic dysfunction to understand the molecular basis of schizophrenia, BP.MS; 15/09159-8 - Development of lipidomic platform to studies and their use in the assessment of response to antipsychotics in patients with schizophrenia, BP.PD; 14/21035-0 - Quantitative proteomics in neural cell lines and organoids derived from induced pluripotent stem cells from schizophrenia patients, BP.PD; 14/14881-1 - Understanding the influence of glycolysis components in the function of oligodendrocytes: linking with findings in schizophrenia, BP.PD; 13/25702-8 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics, BP.JP - associated scholarships

Abstract

Schizophrenia is an incurable and debilitating mental disorder which affects approximately 1% of world population. It is a multifactorial disease involving exogenous and endogenous factors since the neurodevelopment. The molecular mechanisms of the disease are still to be unraveled for an integrated comprehension of the pathobiology. Additionally, biomarkers for diagnosis and for the likelihood of a successful treatment are not existent. Proteomics is, by definition, a suitable tool for investigating multifactorial disorders as schizophrenia. Proteins differentially expressed identified in a given biological condition may pinpoint which pathways are altered leading to a better comprehension of the disorder, and can be used as potential biomarker candidates. This project will perform a pioneer proteome analyses of plasma collected in vivo from patients and controls before and after medication. Our main goals are unraveling biochemical pathways modulated by the medication as well as revealing for the first time proteins that can act as potential biomarkers, which may indicate the likelihood of a successful treatment. Biomarker candidates will be combined in a mass spectrometry-based molecular assay to be evaluated as the first clinical test ever to determine medication response. Furthermore, we intend to contribute in the comprehension of the molecular aspects of schizophrenia. Based in our previous results, we will investigate the sub-proteomes of gray and white matter of four different brain regions from postmortem brains of schizophrenia patients and controls as well as preclinical models such as cultured oligodendrocytes. Our objective is to reveal differentially expressed proteins and their biochemical pathways for understanding their role in the establishment and maintenance of schizophrenia. This project will shed light in the comprehension of the molecular bases of schizophrenia and goes towards the development of a personalized medicine strategy with potential clinical implementation. (AU)

Scientific publications

(44)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

NASCIMENTO, JULIANA M.; GARCIA, SHEILA; SAIA-CEREDA, VERONICA M.; SANTANA, ALINE G.; BRANDAO-TELES, CAROLINE; ZUCCOLI, GIULIANA S.; JUNQUEIRA, DANIELLE G.; REIS-DE-OLIVEIRA, GUILHERME; BALDASSO, PAULO A.; CASSOLI, JULIANA S.; et al. Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia. PROTEOMICS CLINICAL APPLICATIONS, v. 10, n. 12, SI, p. 1148-1158, DEC 2016. (14/14881-1, 15/23049-0, 16/04912-2, 13/08711-3, 14/21035-0)

TAVARES, RAPHAEL; WAJNBERG, GABRIEL; SCHERER, NICOLE DE MIRANDA; PAULETTI, BIANCA ALVES; CASSOLI, JULIANA S.; FERREIRA, CARLOS GIL; PAES LEME, ADRIANA FRANCO; DE ARAUJO-SOUZA, PATRICIA SAVIO; MARTINS-DE-SOUZA, DANIEL; PASSETTI, FABIO. Unveiling alterative splice diversity from human oligodendrocyte proteome data. JOURNAL OF PROTEOMICS, v. 151, n. SI, p. 293-301, JAN 16 2017. (14/14881-1, 09/54067-3, 13/08711-3, 14/10068-4, 10/19278-0)

SILVA-COSTA, LICIA C.; GARCIA-ROSA, SHEILA; SMITH, BRADLEY J.; BALDASSO, PAULO A.; STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL. Blood plasma high abundant protein depletion unintentionally carries over 100 proteins. SEPARATION SCIENCE PLUS, OCT 2019. (13/08711-3, 17/25588-1, 16/07948-8, 18/03422-7, 14/10068-4, 19/05747-3)

SCHMITT, ANDREA; MARTINS-DE-SOUZA, DANIEL; AKBARIAN, SCHAHRAM; CASSOLI, JULIANA S.; EHRENREICH, HANNELORE; FISCHER, ANDRE; FONTEH, ALFRED; GATTAZ, WAGNER F.; GAWLIK, MICHAEL; GERLACH, MANFRED; et al. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, v. 18, n. 5, p. 330-356, 2017. (14/21035-0, 14/10068-4, 14/14881-1, 13/08711-3)

MARTINS-DE-SOUZA, DANIEL. Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. DIALOGUES IN CLINICAL NEUROSCIENCE, v. 16, n. 1, p. 63-73, MAR 2014. (13/08711-3)

STEINER, JOHANN; SCHMITT, ANDREA; SCHROETER, MATTHIAS L.; BOGERTS, BERNHARD; FALKAI, PETER; TURCK, CHRISTOPH W.; MARTINS-DE-SOUZA, DANIEL. S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v. 264, n. 4, p. 311-316, JUN 2014. (13/08711-3)

TURCK, CHRISTOPH W.; GUEST, PAUL C.; MACCARRONE, GIUSEPPINA; ISING, MARCUS; KLOIBER, STEFAN; LUCAE, SUSANNE; HOLSBOER, FLORIAN; MARTINS-DE-SOUZA, DANIEL. Proteomic Differences in Blood Plasma Associated with Antidepressant Treatment Response. FRONTIERS IN MOLECULAR NEUROSCIENCE, v. 10, AUG 31 2017. (14/10068-4, 13/08711-3)

ZUCCOLI, GIULIANA S.; SAIA-CEREDA, VERONICA M.; NASCIMENTO, JULIANA M.; MARTINS-DE-SOUZA, DANIEL. The Energy Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence. FRONTIERS IN NEUROSCIENCE, v. 11, SEP 7 2017. (16/04912-2, 13/08711-3, 14/10068-4, 14/21035-0, 16/07332-7)

CASSOLI, JULIANA S.; IWATA, KEIKO; STEINER, JOHANN; GUEST, PAUL C.; TURCK, CHRISTOPH W.; NASCIMENTO, JULIANA M.; MARTINS-DE-SOUZA, DANIEL. Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. FRONTIERS IN CELLULAR NEUROSCIENCE, v. 10, MAR 3 2016. (14/21035-0, 14/10068-4, 14/14881-1, 13/08711-3)

JOSEPH SMITH, BRADLEY; BRANDAO-TELES, CAROLINE; ZUCCOLI, GIULIANA S.; REIS-DE-OLIVEIRA, GUILHERME; FIORAMONTE, MARIANA; SAIA-CEREDA, VERONICA M.; MARTINS-DE-SOUZA, DANIEL. Protein Succinylation and Malonylation as Potential Biomarkers in Schizophrenia. JOURNAL OF PERSONALIZED MEDICINE, v. 12, n. 9, p. 15-pg., 2022-09-01. (14/10068-4, 16/07948-8, 17/25055-3, 15/23049-0, 18/01410-1, 18/14666-4, 19/05747-3, 16/07332-7, 13/08711-3, 19/00098-7, 17/25588-1)

OLIVEIRA, BRUNO M.; COORSSEN, JENS R.; MARTINS-DE-SOUZA, DANIEL. 2DE: The Phoenix of Proteomics. JOURNAL OF PROTEOMICS, v. 104, p. 11-pg., 2014-06-02. (13/25702-8, 13/08711-3)

SILVA-COSTA, LICIA C.; GARCIA-ROSA, SHEILA; SMITH, BRADLEY J.; BALDASSO, PAULO A.; STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL. Blood plasma high abundant protein depletion unintentionally carries over 100 proteins. SEPARATION SCIENCE PLUS, v. 2, n. 12, p. 8-pg., 2019-10-21. (16/07948-8, 19/05747-3, 17/25588-1, 13/08711-3, 18/03422-7, 14/10068-4)

MARTINS-DE-SOUZA, DANIEL; CASSOLI, JULIANA S.; NASCIMENTO, JULIANA M.; HENSLEY, KENNETH; GUEST, PAUL C.; PINZON-VELASCO, ANDRES M.; TURCK, CHRISTOPH W.. The protein interactome of collapsin response mediator protein-2 (CRMP2/DPYSL2) reveals novel partner proteins in brain tissue. PROTEOMICS CLINICAL APPLICATIONS, v. 9, n. 9-10, p. 15-pg., 2015-10-01. (13/08711-3, 13/25702-8, 14/14881-1, 14/10068-4)

MARTINS-DE-SOUZA, DANIEL. Employing Proteomics to Explore the Metabolic Component of Schizophrenia. BIOLOGICAL PSYCHIATRY, v. 79, n. 9, p. 1-pg., 2016-05-01. (14/10068-4, 13/08711-3)

CASSOLI, JULIANA S.; GUEST, PAUL C.; SANTANA, ALINE G.; MARTINS-DE-SOUZA, DANIEL. Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. PROTEOMICS CLINICAL APPLICATIONS, v. 10, n. 4, p. 14-pg., 2016-04-01. (13/08711-3, 14/14881-1)

RADAIC, ALLAN; MARTINS-DE-SOUZA, DANIEL. The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment. Nanomedicine-Nanotechnology Biology and Medicine, v. 28, AUG 2020. (17/25588-1, 13/08711-3, 18/03673-0)

MARTINS-DE-SOUZA, DANIEL; GUEST, PAUL C.; STEINER, JOHANN. A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v. 270, n. 1, p. 127-134, FEB 2020. (17/25588-1, 13/08711-3)

CASSOLI, JULIANA S.; BRANDAO-TELES, CAROLINE; SANTANA, ALINE G.; SOUZA, GUSTAVO H. M. F.; MARTINS-DE-SOUZA, DANIEL. Ion Mobility-Enhanced Data-Independent Acquisitions Enable a Deep Proteomic Landscape of Oligodendrocytes. PROTEOMICS, v. 17, n. 21, NOV 2017. (15/23049-0, 14/14881-1, 13/08711-3, 14/10068-4)

GARCEZ, PATRICIA P.; NASCIMENTO, JULIANA MINARDI; DE VASCONCELOS, JANAINA MOTA; DA COSTA, RODRIGO MADEIRO; DELVECCHIO, RODRIGO; TRINDADE, PABLO; LOIOLA, ERICK CORREIA; HIGA, LUIZA M.; CASSOLI, JULIANA S.; VITORIA, GABRIELA; et al. Zika virus disrupts molecular fingerprinting of human neurospheres. SCIENTIFIC REPORTS, v. 7, JAN 23 2017. (14/21035-0, 14/10068-4, 13/08711-3, 14/14881-1)

NASCIMENTO, JULIANA M.; MARTINS-DE-SOUZA, DANIEL. The proteome of schizophrenia. NPJ SCHIZOPHRENIA, v. 1, 2015. (14/10068-4, 13/08711-3)

DE ALMEIDA, VALERIA; MARTINS-DE-SOUZA, DANIEL. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v. 268, n. 7, p. 727-737, OCT 2018. (14/10068-4, 13/08711-3)

VELASQUEZ, ERIKA; NOGUEIRA, FABIO C. S.; VELASQUEZ, INGRID; SCHRNITT, ANDREA; FALKAI, PETER; DOMONT, GILBERTO B.; MARTINS-DE-SOUZA, DANIEL. Synaptosomal Proteome of the Orbitofrontal Cortex from Schizophrenia Patients Using Quantitative Label-Free and iTRAQ-Based Shotgun Proteomics. JOURNAL OF PROTEOME RESEARCH, v. 16, n. 12, p. 4481-4494, DEC 2017. (14/10068-4, 13/08711-3)

CASSOLI, JULIANA S.; GUEST, PAUL C.; SANTANA, ALINE G.; MARTINS-DE-SOUZA, DANIEL. Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. PROTEOMICS CLINICAL APPLICATIONS, v. 10, n. 4, SI, p. 442-455, APR 2016. (14/14881-1, 13/08711-3)

MARTINS-DE-SOUZA, DANIEL; CASSOLI, JULIANA S.; NASCIMENTO, JULIANA M.; HENSLEY, KENNETH; GUEST, PAUL C.; PINZON-VELASCO, ANDRES M.; TURCK, CHRISTOPH W.. The protein interactome of collapsin response mediator protein-2 (CRMP2/DPYSL2) reveals novel partner proteins in brain tissue. PROTEOMICS CLINICAL APPLICATIONS, v. 9, n. 9-10, SI, p. 817-831, OCT 2015. (14/10068-4, 14/14881-1, 13/25702-8, 13/08711-3)

OLIVEIRA, BRUNO M.; COORSSEN, JENS R.; MARTINS-DE-SOUZA, DANIEL. 2DE: The Phoenix of Proteomics. JOURNAL OF PROTEOMICS, v. 104, n. SI, p. 140-150, JUN 2 2014. (13/25702-8, 13/08711-3)

CAFE-MENDES, C. C.; FERRO, E. S.; TORRAO, A. S.; CRUNFLI, F.; RIOLI, V.; SCHMITT, A.; FALKAI, P.; BRITTO, L. R.; TURCK, C. W.; MARTINS-DE-SOUZA, D.. Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. JOURNAL OF PROTEOMICS, v. 151, n. SI, p. 97-105, JAN 16 2017. (14/10068-4, 13/08711-3)

CASSOLI, JULIANA SILVA; GUEST, PAUL C.; MALCHOW, BEREND; SCHMITT, ANDREA; FALKAI, PETER; MARTINS-DE-SOUZA, DANIEL. Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ SCHIZOPHRENIA, v. 1, 2015. (14/10068-4, 14/14881-1, 13/08711-3)

MARTINS-DE-SOUZA, DANIEL; SOLARIA, FIORELLA A.; GUEST, PAUL C.; ZAHEDI, RENE P.; STEINER, JOHANN. Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response. NPJ SCHIZOPHRENIA, v. 1, 2015. (14/10068-4, 13/25702-8, 13/08711-3)

SANTOS DE OLIVEIRA, PERCILLIA VICTORIA; GARCIA-ROSA, SHEILA; AZEVEDO SACHETTO, ANA TERESA; SOARES MORETTI, ANA IOCHABEL; DEBBAS, VICTOR; DE BESSA, TIPHANY CORALIE; SILVA, NATHALIA TENGUAN; PEREIRA, ALEXANDRE DA COSTA; MARTINS-DE-SOUZA, DANIEL; SANTORO, MARCELO LARAMI; et al. Protein disulfide isomerase plasma levels in healthy humans reveal proteomic signatures involved in contrasting endothelial phenotypes. REDOX BIOLOGY, v. 22, APR 2019. (17/25588-1, 18/07511-4, 17/19866-9, 14/20595-1, 13/08711-3, 13/25177-0, 14/10068-4, 13/07937-8)

DEZONNE, ROMULO SPERDUTO; SARTORE, RAFAELA COSTA; NASCIMENTO, JULIANA MINARDI; SAIA-CEREDA, VERONICA M.; ROMAO, LUCIANA FERREIRA; ALVES-LEON, SONIZA VIEIRA; DE SOUZA, JORGE MARCONDES; MARTINS-DE-SOUZA, DANIEL; REHEN, STEVENS KASTRUP; ALCANTARA GOMES, FLVIA CARVALHO. Derivation of Functional Human Astrocytes from Cerebral Organoids. SCIENTIFIC REPORTS, v. 7, MAR 27 2017. (14/21035-0, 14/10068-4, 13/08711-3, 16/07332-7)

SUSSULINI, ALESSANDRA; ERBOLATO, HELENA MUNHOZ; PESSOA, GUSTAVO DE SOUZA; ZEZZI ARRUDA, MARCO AURELIO; STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL. Elemental fingerprinting of schizophrenia patient blood plasma before and after treatment with antipsychotics. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v. 268, n. 6, p. 565-570, SEP 2018. (16/07384-7, 15/13229-1, 13/08711-3, 14/10068-4, 14/50867-3)

DAKIC, VANJA; NASCIMENTO, JULIANA MINARDI; SARTORE, RAFAELA COSTA; MACIEL, RENATA DE MORAES; DE ARAUJO, DRAULIO B.; RIBEIRO, SIDARTA; MARTINS-DE-SOUZA, DANIEL; REHEN, STEVENS K.. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. SCIENTIFIC REPORTS, v. 7, OCT 9 2017. (14/21035-0, 14/10068-4, 13/08711-3)

VENDRAMINI, PEDRO H.; GATTAZ, WAGNER F.; SCHMITT, ANDREA; FALKAI, PETER; EBERLIN, MARCOS N.; MARTINS-DE-SOUZA, DANIEL. Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. SCHIZOPHRENIA RESEARCH, v. 177, n. 1-3, p. 67-69, NOV 2016. (14/10068-4, 13/08711-3)

SAIA-CEREDA, VERONICA M.; CASSOLI, JULIANA S.; SCHMITT, ANDREA; FALKAI, PETER; MARTINS-DE-SOUZA, DANIEL. Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. SCHIZOPHRENIA RESEARCH, v. 177, n. 1-3, p. 70-77, NOV 2016. (14/10068-4, 14/14881-1, 13/08711-3)

SAIA-CEREDA, VERONICA M.; CASSOLI, JULIANA S.; MARTINS-DE-SOUZA, DANIEL; NASCIMENTO, JULIANA M.. Psychiatric disorders biochemical pathways unraveled by human brain proteomics. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v. 267, n. 1, p. 3-17, FEB 2017. (14/21035-0, 14/14881-1, 13/08711-3)

AQUINO, ADRIANO; ALEXANDRINO, GUILHERME L.; GUEST, PAUL C.; AUGUSTO, FABIO; GOMES, ALEXANDRE F.; MURGU, MICHAEL; STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL. Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. FRONTIERS IN PSYCHIATRY, v. 9, MAY 25 2018. (17/25588-1, 15/08201-0, 15/09159-8, 13/08711-3, 14/10068-4)

GUEST, PAUL C.; GUEST, FRANCESCA L.; MARTINS-DE SOUZA, DANIEL. Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, v. 19, n. 6, JUN 2016. (13/08711-3)

STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL; SCHILTZ, KOLJA; SARNYAI, ZOLTAN; WESTPHAL, SABINE; ISERMANN, BEREND; DOBROWOLNY, HENRIK; TURCK, CHRISTOPH W.; BOGERTS, BERNHARD; BERNSTEIN, HANS-GERT; et al. Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. FRONTIERS IN CELLULAR NEUROSCIENCE, v. 8, NOV 18 2014. (13/08711-3)

SAIA-CEREDA, VERONICA M.; CASSOLI, JULIANA S.; SCHMITT, ANDREA; FALKAI, PETER; NASCIMENTO, JULIANA M.; MARTINS-DE-SOUZA, DANIEL. Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v. 265, n. 7, p. 601-612, OCT 2015. (14/21035-0, 14/10068-4, 14/14881-1, 13/08711-3)

GUEST, PAUL C.; IWATA, KEIKO; KATO, TAKAHIRO A.; STEINER, JOHANN; SCHMITT, ANDREA; TURCK, CHRISTOPH W.; MARTINS-DE-SOUZA, DANIEL. MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. FRONTIERS IN CELLULAR NEUROSCIENCE, v. 9, MAY 12 2015. (13/08711-3)

NASCIMENTO, JULIANA MINARDI; SAIA-CEREDA, VERONICA M.; SARTORE, RAFAELA C.; DA COSTA, RODRIGO MADEIRO; SCHITINE, CLARISSA S.; FREITAS, HERCULES REZENDE; MURGU, MICHAEL; DE MELO REIS, RICARDO A.; REHEN, STEVENS K.; MARTINS-DE-SOUZA, DANIEL. Human Cerebral Organoids and Fetal Brain Tissue Share Proteomic Similarities. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, v. 7, NOV 28 2019. (14/21035-0, 14/10068-4, 13/08711-3, 16/07332-7)

NASCIMENTO, JULIANA M.; GARCIA, SHEILA; SAIA-CEREDA, VERONICA M.; SANTANA, ALINE G.; BRANDAO-TELES, CAROLINE; ZUCCOLI, GIULIANA S.; JUNQUEIRA, DANIELLE G.; REIS-DE-OLIVEIRA, GUILHERME; BALDASSO, PAULO A.; CASSOLI, JULIANA S.; et al. Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia. PROTEOMICS CLINICAL APPLICATIONS, v. 10, n. 12, p. 11-pg., 2016-12-01. (15/23049-0, 14/21035-0, 16/04912-2, 13/08711-3, 14/14881-1)

TAVARES, RAPHAEL; WAJNBERG, GABRIEL; SCHERER, NICOLE DE MIRANDA; PAULETTI, BIANCA ALVES; CASSOLI, JULIANA S.; FERREIRA, CARLOS GIL; PAES LEME, ADRIANA FRANCO; DE ARAUJO-SOUZA, PATRICIA SAVIO; MARTINS-DE-SOUZA, DANIEL; PASSETTI, FABIO. Unveiling alterative splice diversity from human oligodendrocyte proteome data. JOURNAL OF PROTEOMICS, v. 151, p. 9-pg., 2017-01-16. (14/10068-4, 10/19278-0, 09/54067-3, 14/14881-1, 13/08711-3)

CAFE-MENDES, C. C.; FERRO, E. S.; TORRAO, A. S.; CRUNFLI, F.; RIOLI, V.; SCHMITT, A.; FALKAI, P.; BRITTO, L. R.; TURCK, C. W.; MARTINS-DE-SOUZA, D.. Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. JOURNAL OF PROTEOMICS, v. 151, p. 9-pg., 2017-01-16. (14/10068-4, 13/08711-3)

Filed patent(s) as a result of this research project